<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:department>Institute of Human Genetics</gtr:department><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/DD56FF7E-A7C4-4631-B930-C2530F947C53"><gtr:id>DD56FF7E-A7C4-4631-B930-C2530F947C53</gtr:id><gtr:firstName>Prabhakar</gtr:firstName><gtr:surname>Rajan</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0500482"><gtr:id>7543B3EA-D5E4-4903-BBE3-CC0BF567B215</gtr:id><gtr:title>The Role Of Sam68 (Src-Associated Substrate During Mitosis Of 68kda) And Interacting Protein Partners in Prostate Cancer</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0500482</gtr:grantReference><gtr:abstractText>We aim to find new ways of diagnosing and treating prostate cancer; the commonest cancer in men, with about 30,000 new cases diagnosed each year in the UK. The prostate is a gland found below the bladder and produces a component of semen. In older men, cells in the prostate can become cancerous, but the cancer can be cured if treated early.
The causes of prostate cancer are not fully understood, but changes in proteins in cancer cells may make them more likely to spread. These proteins differ only slightly from normal, but can make the cells spread to other parts of the body, which is very bad news. 
Imagine a film editor putting together bits of footage to create a story?.by rearranging bits of film in a slightly different order, a slightly different story is told. Similarly, bits of genes - the recipe to make proteins - can be read differently by the cell to make slightly different proteins: We call this alternative splicing.
We are trying to discover how proteins produced by alternative splicing make prostate cancer worse. We hope to find new ways to diagnose prostate cancer earlier and new drugs to prevent spread of the disease.</gtr:abstractText><gtr:technicalSummary>Prostate cancer (CaP) is the second commonest cancer in the UK. Despite androgen deprivation and second-line endocrine therapy, clinical relapse can occurs with a median 1-year survival. Current investigation into CaP biology is focused on two major clinical challenges; hormone-refractory states (HRCaP) and metastasis. The development of HRCaP is associated with constitutively active Src-kinase activity and downstream pathways. One of the major substrates for Src-family kinases is Sam68 (Src-Associated Substrate During Mitosis Of 68kda), which is hyperphosphorylated in high-grade CaP. Sam68 plays important but not completely understood roles in both ras-signalling and RNA splicing, particularly leading to incorporation of alternative exons in the CD44 gene, associated with metastasis. Sam68 is also linked with apoptosis and cell-cycle control. During investigations into splicing in the testis, Dr David Elliott (Institute of Human Genetics, IHG) discovered interactions between SAM68 and other proteins (ASPP1, RANBPM, hnRNPA2/B1) implicated in cancer. With Professor Hing Leung (Northern Institute for Cancer Research, NICR), we have developed this project to comprehensively define the role of Sam68 and interacting proteins in splicing, apoptosis and cell-signalling in CaP. This will provide researchers in oncology with new insight, linking splicing and carcinogenesis. The expression of Sam68 and interacting proteins will be studied using tissue microarrays and clinical specimens (established in NICR) correlating protein expression with cancer progression, response to treatment, metastasis and survival. I will verify protein-protein interactions using co-immunoprecipitation techniques (IHG) and in real-time using FRET-FLIM (Institute for Cellular and Molecular Biosciences). Using mammalian expression vectors, I will transfect Sam68 and interacting proteins into human CaP cell lines (such as LNCaP and PC3), and study the effects of Sam68 on important signalling pathways in HRCaP (ras/MAPK, PI3 kinase/AKT) using cell-signaling kits (performed in NICR). In a CD44 variable exon minigene experiment, the effect of Sam68 on regulation of splicing will be examined using targeted multi-gene siRNA blockade (established in NICR), FACS analysis and real time-PCR. Using expression vectors and siRNA, I will investigate the link between Sam68 and apoptosis (FACS and apoptosis kits) by focussing on the pro-apoptotic protein ASPP1, which regulates p53 and deletion of which can be important in cancers expressing wild-type p53. Once sufficient biological evidence has been collected, the ultimate goal will be to begin identification of putative drug targets in hormone-refractory and metastatic CaP to improve quality of life, prognosis, and outcome.</gtr:technicalSummary><gtr:fund><gtr:end>2008-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>178048</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Talk to local Prostate UK support group on PSA</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>3D7A1167-5B0F-45F1-B1A6-42B4D04A2273</gtr:id><gtr:impact>Talk on roles of PSA in prostate cancer to patients from local support group

None</gtr:impact><gtr:outcomeId>rJ7kC7xibn6</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NHS Greater Glasgow and Clyde Endowments</gtr:department><gtr:description>NHS GGC Endowments</gtr:description><gtr:end>2012-05-02</gtr:end><gtr:fundingOrg>NHS Greater Glasgow and Clyde (NHSGGC)</gtr:fundingOrg><gtr:id>A5C75DA5-F98D-461B-AC93-33E0529CF757</gtr:id><gtr:outcomeId>gALbsVwyUwS0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>675000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cancer Research UK Clinician Scientist Fellowship</gtr:description><gtr:end>2017-05-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>DF205A38-B02A-4CD2-976C-C681C5C2BAAA</gtr:id><gtr:outcomeId>dQwqUeDCvMj</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>WT/AMS Starter Grant for Clinical Lecturers</gtr:description><gtr:end>2011-10-02</gtr:end><gtr:fundingOrg>Academy of Medical Sciences (AMS)</gtr:fundingOrg><gtr:id>11866DD9-CF19-488C-92D6-687D25ACC986</gtr:id><gtr:outcomeId>gbHhH18JYie0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>5EDA26BD-F71D-415C-A77D-4F97D6450D75</gtr:id><gtr:title>Proteomic identification of heterogeneous nuclear ribonucleoprotein L as a novel component of SLM/Sam68 Nuclear Bodies.</gtr:title><gtr:parentPublicationTitle>BMC cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/926b354ae4e38e2c054bd1f60c23a749"><gtr:id>926b354ae4e38e2c054bd1f60c23a749</gtr:id><gtr:otherNames>Rajan P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1471-2121</gtr:issn><gtr:outcomeId>0641F85E966</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7242D78F-A067-41EA-A92B-97F47FF82EE4</gtr:id><gtr:title>The role of the RNA-binding protein Sam68 in mammary tumourigenesis.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/35ef267d53e0599ce44b4a222ab80ecf"><gtr:id>35ef267d53e0599ce44b4a222ab80ecf</gtr:id><gtr:otherNames>Elliott DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>LEzMVhmP3EY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE9F1DBB-C873-43A1-BA20-A364B86BD91B</gtr:id><gtr:title>Alternative splicing and biological heterogeneity in prostate cancer.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/926b354ae4e38e2c054bd1f60c23a749"><gtr:id>926b354ae4e38e2c054bd1f60c23a749</gtr:id><gtr:otherNames>Rajan P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1759-4812</gtr:issn><gtr:outcomeId>n312jcLP29r</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2555E21-1B30-4EBE-A82A-38AD9C7ED9CD</gtr:id><gtr:title>The RNA-binding and adaptor protein Sam68 modulates signal-dependent splicing and transcriptional activity of the androgen receptor.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/926b354ae4e38e2c054bd1f60c23a749"><gtr:id>926b354ae4e38e2c054bd1f60c23a749</gtr:id><gtr:otherNames>Rajan P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>D9234749A0E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4731BE3A-E242-44E7-97C0-F17FAD04B470</gtr:id><gtr:title>Targeting alternative splicing in prostate oncology.</gtr:title><gtr:parentPublicationTitle>Discovery medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7208eb46679b472c9f0252903acf90fd"><gtr:id>7208eb46679b472c9f0252903acf90fd</gtr:id><gtr:otherNames>Carling PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1539-6509</gtr:issn><gtr:outcomeId>BjSEQAcN7Qx</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89FEA283-8034-4E6C-956C-C9AC8204C23E</gtr:id><gtr:title>The RNA helicase p68 is a novel androgen receptor coactivator involved in splicing and is overexpressed in prostate cancer.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b27ff50d0bfaf49d2437a6da8c0342d6"><gtr:id>b27ff50d0bfaf49d2437a6da8c0342d6</gtr:id><gtr:otherNames>Clark EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>pBWQb9Ke4SV</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5EF7702A-472C-4F7C-87B5-5E20E1E37299</gtr:id><gtr:title>Identification of novel androgen-regulated pathways and mRNA isoforms through genome-wide exon-specific profiling of the LNCaP transcriptome.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/926b354ae4e38e2c054bd1f60c23a749"><gtr:id>926b354ae4e38e2c054bd1f60c23a749</gtr:id><gtr:otherNames>Rajan P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>SbVLCHg1UGR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F56EDEA7-7AE5-45C1-A596-345C3AFBBF26</gtr:id><gtr:title>Regulation of gene expression by the RNA-binding protein Sam68 in cancer.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/926b354ae4e38e2c054bd1f60c23a749"><gtr:id>926b354ae4e38e2c054bd1f60c23a749</gtr:id><gtr:otherNames>Rajan P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>6931F535032</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0500482</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>